These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38690856)

  • 1. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer.
    Xu J; Qi H; Wang Z; Wang L; Steurer B; Cai X; Liu J; Aliper A; Zhang M; Ren F; Zhavoronkov A; Ding X
    J Med Chem; 2024 May; 67(10):8161-8171. PubMed ID: 38690856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors.
    Zhang H; Jing L; Liu M; Goto M; Lai F; Liu X; Sheng L; Yang Y; Yang Y; Li Y; Chen X; Lee KH; Xiao Z
    Eur J Med Chem; 2021 Nov; 223():113634. PubMed ID: 34147745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.
    Czodrowski P; Mallinger A; Wienke D; Esdar C; Pöschke O; Busch M; Rohdich F; Eccles SA; Ortiz-Ruiz MJ; Schneider R; Raynaud FI; Clarke PA; Musil D; Schwarz D; Dale T; Urbahns K; Blagg J; Schiemann K
    J Med Chem; 2016 Oct; 59(20):9337-9349. PubMed ID: 27490956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential.
    Fujimoto J; Hirayama T; Hirata Y; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
    Bioorg Med Chem; 2017 Jun; 25(12):3018-3033. PubMed ID: 28392276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
    Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
    Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding patterns and structure-activity relationship of CDK8 inhibitors.
    Ma D; Chen X; Shen XB; Sheng LQ; Liu XH
    Bioorg Chem; 2020 Mar; 96():103624. PubMed ID: 32078847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New CDK8 inhibitors as potential anti-leukemic agents - Design, synthesis and biological evaluation.
    Solum E; Hansen TV; Aesoy R; Herfindal L
    Bioorg Med Chem; 2020 May; 28(10):115461. PubMed ID: 32245563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition.
    Chen M; Li J; Liang J; Thompson ZS; Kathrein K; Broude EV; Roninson IB
    Cells; 2019 Nov; 8(11):. PubMed ID: 31717492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
    Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
    Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics.
    Zhang L; Cheng C; Li J; Wang L; Chumanevich AA; Porter DC; Mindich A; Gorbunova S; Roninson IB; Chen M; McInnes C
    J Med Chem; 2022 Feb; 65(4):3420-3433. PubMed ID: 35114084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
    Dale T; Clarke PA; Esdar C; Waalboer D; Adeniji-Popoola O; Ortiz-Ruiz MJ; Mallinger A; Samant RS; Czodrowski P; Musil D; Schwarz D; Schneider K; Stubbs M; Ewan K; Fraser E; TePoele R; Court W; Box G; Valenti M; de Haven Brandon A; Gowan S; Rohdich F; Raynaud F; Schneider R; Poeschke O; Blaukat A; Workman P; Schiemann K; Eccles SA; Wienke D; Blagg J
    Nat Chem Biol; 2015 Dec; 11(12):973-980. PubMed ID: 26502155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
    Mallinger A; Schiemann K; Rink C; Stieber F; Calderini M; Crumpler S; Stubbs M; Adeniji-Popoola O; Poeschke O; Busch M; Czodrowski P; Musil D; Schwarz D; Ortiz-Ruiz MJ; Schneider R; Thai C; Valenti M; de Haven Brandon A; Burke R; Workman P; Dale T; Wienke D; Clarke PA; Esdar C; Raynaud FI; Eccles SA; Rohdich F; Blagg J
    J Med Chem; 2016 Feb; 59(3):1078-101. PubMed ID: 26796641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives.
    Ono K; Banno H; Okaniwa M; Hirayama T; Iwamura N; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
    Bioorg Med Chem; 2017 Apr; 25(8):2336-2350. PubMed ID: 28302507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
    Hofmann MH; Mani R; Engelhardt H; Impagnatiello MA; Carotta S; Kerenyi M; Lorenzo-Herrero S; Böttcher J; Scharn D; Arnhof H; Zoephel A; Schnitzer R; Gerstberger T; Sanderson MP; Rajgolikar G; Goswami S; Vasu S; Ettmayer P; Gonzalez S; Pearson M; McConnell DB; Kraut N; Muthusamy N; Moll J
    Mol Cancer Ther; 2020 Apr; 19(4):1018-1030. PubMed ID: 32024684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.
    Schiemann K; Mallinger A; Wienke D; Esdar C; Poeschke O; Busch M; Rohdich F; Eccles SA; Schneider R; Raynaud FI; Czodrowski P; Musil D; Schwarz D; Urbahns K; Blagg J
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1443-51. PubMed ID: 26852363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors.
    Xi M; Chen T; Wu C; Gao X; Wu Y; Luo X; Du K; Yu L; Cai T; Shen R; Sun H
    Eur J Med Chem; 2019 Feb; 164():77-91. PubMed ID: 30594029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7).
    Ji W; Du G; Jiang J; Lu W; Mills CE; Yuan L; Jiang F; He Z; Bradshaw GA; Chung M; Jiang Z; Byun WS; Hinshaw SM; Zhang T; Gray NS
    Eur J Med Chem; 2024 Oct; 276():116613. PubMed ID: 39004018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK8 Kinase Activity Promotes Glycolysis.
    Galbraith MD; Andrysik Z; Pandey A; Hoh M; Bonner EA; Hill AA; Sullivan KD; Espinosa JM
    Cell Rep; 2017 Nov; 21(6):1495-1506. PubMed ID: 29117556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and Development of Cyclin-Dependent Kinase 8 Inhibitors.
    Lv X; Tian Y; Li S; Cheng K; Huang X; Kong H; Liao C; Xie Z
    Curr Med Chem; 2020; 27(32):5429-5443. PubMed ID: 30947649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mediator kinase inhibition reverses castration resistance of advanced prostate cancer.
    Li J; Hilimire TA; Liu Y; Wang L; Liang J; Gyorffy B; Sikirzhytski V; Ji H; Zhang L; Cheng C; Ding X; Kerr KR; Dowling CE; Chumanevich AA; Mack ZT; Schools GP; Lim CU; Ellis L; Zi X; Porter DC; Broude EV; McInnes C; Wilding G; Lilly MB; Roninson IB; Chen M
    J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38546787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.